Introduction {#Sec1}
============

Acute brain failure (ABF) is a common complication of critical illness and is associated with increased short and long-term mortality \[[@CR1]\]. While delirium only reflects alterations in the content of consciousness, ABF reflects change in both content and level of consciousness \[[@CR1]\]. The risk of ABF in the ICU is greater in older patients with more severe acute disease and greater comorbidities \[[@CR1]\]. An expert panel recently recommended using the term acute encephalopathy (AE) to refer to alterations of consciousness in critically ill patients \[[@CR2]\]; the definition of AE that is consistent with our previous definition of ABF. Hence we decided to use the term AE instead of ABF.

Cefepime is a fourth generation cephalosporin, with an extended spectrum of antimicrobial activity that is usually reserved to treat suspected or confirmed severe nosocomial infections. Because cefepime is excreted predominantly unchanged, a reduction in renal function increases the elimination half-life, leading to drug accumulation in blood and CSF \[[@CR3]\]. Supratherapeutic levels of cefepime can cause neurological symptoms that include encephalopathy, myoclonus, seizures, hallucinations, and coma \[[@CR4]\].

Although cefepime-induced neurotoxicity (CIN) typically occurs in patients with renal impairment in whom the dose of the antibiotic is not appropriately adjusted, neurological symptoms have been reported despite dose adjustments \[[@CR4]--[@CR7]\]. The incidence of CIN has been reported to range from 1 to 15% \[[@CR3], [@CR4], [@CR8]\]. Yet, the association of cefepime with delirium in the ICU has been questioned \[[@CR9]\]. We conducted a case--control study to determine the association between cefepime use and AE in a large ICU population.

Methods {#Sec2}
=======

The study was approved by the Mayo Clinic institutional review board (IRBe number 14-001118). This study was conducted in accordance with the declaration of Helsinki.

Study Design and Setting {#Sec3}
------------------------

We enrolled consecutive patients who had been admitted to the ICUs in Mayo Clinic Rochester, Minnesota between July 1, 2004 and December 31, 2015. Patients admitted to the Neuroscience, Pediatric and Neonatal ICUs were excluded from the study population. We have previously defined the concept of ABF, electronic search strategy, derivation and validation of the search strategy and grading of ABF \[[@CR1], [@CR10]\]. However as per the recent guidelines, we decided to use the updated term AE instead of ABF. Cases were defined as patients who had developed AE during the ICU stay. AE was defined as having delirium (positive Confusion Assessment Method for the ICU \[CAM-ICU\]) or depressed level of consciousness (by two consecutive scores of Glasgow Coma Scale \[GCS\] \< 15 and/or Full Outline of Unresponsiveness \[FOUR\] score \< 16) in the absence of deep sedation (Richmond Agitation Sedation Scale \[RASS\] \< −3). For ventilated patients, GCS score of \< 11 and FOUR scores of \< 13 were considered abnormal. Deeply sedated patients (defined by a RASS score -3 or lower) were excluded because a reliable neurological examination cannot be performed in these instances. To focus on cases which were more likely to develop delirium as part of their ICU course rather than as a consequence of their presenting disease, patients who developed AE in the first 6 h in the ICU were excluded. AE duration was also calculated for the cases (i.e. time from when AE was first noticed until when it resolved). We used a minimum duration of 4 h to exclude AE caused by sedation and to minimize errors, as including these patients could overestimate the incidence of AE.

After identifying patients with AE (57,726), we randomly selected 14,645 cases with AE and 14,645 controls from the general ICU population. The case: control ratio in our study was 1:1 and the controls were matched within 0.1 standard deviation of cases, which is more stringent than the typical caliper width considered optimal (i.e. within 0.2 standard deviation) \[[@CR11]\].

Cefepime use in the ICU {#Sec4}
-----------------------

Cefepime was used for a wide array of infections, including hospital-acquired pneumonia, febrile neutropenia, skin/soft tissue infections, blood stream infections, intracranial infections/meningitis, urinary tract infections etc. The use of cefepime for treating specific microorganisms and the dosing of the antibiotic (including adjustments for patients with acute or chronic kidney injury) was based on the dosing recommendations from the Mayo Clinic antimicrobial therapy guide, which is developed by experts in our Infectious Diseases division and undergoes timely updates to account for the changes in the prevalence of specific organisms/infections (and resistance rates) in our local environment. Cefepime serum levels are not checked in our practice; hence they were not available for this study. The dosing of cefepime is constantly monitored by an ICU pharmacist and the doses are adjusted based on frequent reassessment of the creatinine clearance. The dosing for cefepime used in our hospital is shown in Table [1](#Tab1){ref-type="table"}.Table 1Dosing of cefepimeCreatinine clearance (ml/min)DosingMost infections More than 601000--2000 mg q12h 30--591000--2000 mg q24h 10--29500--1000 mg q24h \< 10 or anuric250--500 mg q24h Hemodialysis250--500 mg q24h (given after hemodialysis on dialysis days) Alternative(Less preferred): 2000 mg three times per week after hemodialysisLife threatening infections, systemic pseudomonal infections, and neutropenic fever More than 602000 mg q8h 30--592000 mg q12h 10--292000 mg q24h \< 10 or anuric1000 mg q24h Hemodialysis1000 mg q24h (given after hemodialysis on the dialysis days)

Data Sources {#Sec5}
------------

We extracted the raw data from the electronic medical records using the ICU Data Mart. The steps of development of this database, data security and validation of the demographics have been previously reported \[[@CR12], [@CR13]\]. The recorded data included age, sex, comorbities including past medical history of hypertension, diabetes mellitus, diabetes with complications, myocardial infarction, congestive heart failure, peripheral vascular disease, dementia, cerebrovascular accident, hemiplegia/paraplegia, asthma or chronic obstructive pulmonary disease (COPD), peptic ulcer, moderate/severe liver disease, cirrhosis, renal failure, and malignancy. Acute kidney injury (AKI) was defined according to the Kidney Disease Improving Global Outcome (KDIGO) criteria and we have previously reported the development and validation of the electronic algorithm for its identification \[[@CR14]\]. We used AKI separately and also combined AKI and chronic kidney disease (CKD) for analyses and referred to them as renal disease. A Charlson comorbidity index (CCI), 24-h Acute Physiology and Chronic Health Evaluation III (APACHE III) score and presence of shock were obtained using previously validated computerized algorithms at out institution \[[@CR13], [@CR15], [@CR16]\]. ICU Data Mart was also used to extract the data on use of sedatives and the use of cefepime.

Statistical Methods and Analyses {#Sec6}
--------------------------------

Descriptive summaries were presented as frequencies and percentages or median and interquartile range as appropriate. Propensity score matching was done using age, CCI, APACHE III score at 24 h, and invasive ventilator use as variables of interest (Fig. [1](#Fig1){ref-type="fig"}). The baseline and post propensity score matching comparisons between the cases and controls has been shown in supplementary table 1. These variables were chosen for propensity matching as these have been shown to be strongly associated with AE and would have confounded the results \[[@CR1]\]. We decided not to include sepsis as part of the propensity score matching, as APACHE III score can be co-linear and thus produce redundancy. Comparisons between subjects with and without AE were performed using *χ*^2^ Chi square tests for categorical variables. Wilcoxon rank sum tests were used to compare means for continuous variable. In this study we used two types of outcomes: (1) a binary outcome (AE presence or absence) for which AE was analyzed using logistic regression and thus the associations were presented as odds ratios and corresponding 95% confidence intervals, whereas and (2) a continuous outcome (i.e. AE duration) that was analyzed using multivariable linear regression model and presented as parameter estimate, which is a slope estimate. The four variables that were used for propensity matching were not used for multivariable analyses. Due to large sample size, variables having a *p* value of ≤ 0.05 on univariate analysis were considered as candidates in the multivariable logistic regression model building. Further analysis was also performed in a similar manner using univariate and multivariable linear regression with AE days as a continuous outcome. The area under ROC curve (receiver operating characteristics curve) for the model used for matching was 0.733, for the multivariable model with AKI was 0.611 and for renal disease was 0.600. All tests were two sided and *p* values less than 0.05 were considered statistically significant. All analyses were performed using SAS version 9.4 (SAS Inc, Cary, NC).Fig. 1Propensity score matching was done using age, Charlson score, APACHE III score at 24 h, and invasive ventilator use. *APACHE III* Acute physiology and chronic health evaluation, *ABF* Acute brain failure

Results {#Sec7}
=======

The initial total numbers of ICU admissions during our study period were 152,999. AE was present in 57,726 (37.7%) ICU admissions and among them 4571 (7.9%) had received cefepime. The prevalence of AE among patients who received cefepime was higher in patients who developed AKI \[3508 (64.4%) vs 1937 (35.6%), *p* \< 0.001\] and those who had renal disease (AKI and CKD) \[3130 (65.8%) vs 1625 (34.2%), *p* \< 0.001\].

For the case--control analyses, we identified 14,645 cases that were diagnosed with AE and 14,645 propensity score matched controls. The details of the cases and controls are shown in Table [2](#Tab2){ref-type="table"}. Cefepime was administered to 1241 (4.2%) patients and they were more likely to develop AE (4.9% vs 3.6%, OR 1.4 \[95% CI 1.2--1.5\], *p* \< 0.001). The prevalence of AE among patients who received cefepime was higher in patients who developed AKI \[488 (64.7%) vs 225 (46.2%), *p* \< 0.001\] and those with renal disease \[522 (62.7%) vs 191 (46.8%), *p* \< 0.001\].Table 2Demographics and characteristics of cases and controlsAE absent (14,645)AE present (14,645)Total (29,290)*p* valueAge67.4 (56.1--769)67.6 (55.0--78.0)67.5 (55.6--77.5)0.353Males8949 (61.1)8442 (57.6)17,391 (59.4)\< 0.001Charlson score5.0 (3.0--7.0)5.0 (3.0--7.0)5.0 (3.0--7.0)0.014Asthma1119 (7.6)1106 (7.6)2225 (7.6)0.774CHF1736 (11.9)1699 (11.6%)3435 (11.7%)0.502COPD1679 (11.5)1976 (13.5)3655 (12.5)\< 0.001Stroke1264 (8.6)1581 (10.8)2845 (9.7)\< 0.001Cancers3936 (29.9)4055 (27.7)7991 (27.3)0.118Chronic pulmonary disease2657 (18.1)2917 (19.9)5574 (19.0)\< 0.001Peripheral vascular disease700 (4.8)775 (5.3)1457 (5.0)0.045Cirrhosis569 (3.9)665 (4.5)1234 (4.2)0.005DM3427 (23.4)3458 (23.6)6885 (23.5)0.669Dementia109 (0.7)396 (2.7)505 (1.7)\< 0.001Invasive vent9950 (67.9)7550 (51.6)16,406 (56.0)\< 0.001MI1541 (10.5)1491 (10.2)3032 (10.4)0.338Moderate/severe kidney disease2149 (14.7%)2184 (14.9%)4333 (14.8%)0.565APACHE III at 24 h67.0 (53.0--82.0)68.0 (55.0--84.0)68.0 (54.0--83.0)\< 0.001Shock5965 (40.7)7138 (48.7)13,103 (44.7)\< 0.001AKI5838 (39.9)8580 (58.6)14,418 (49.2)\< 0.001Midazolam4825 (32.9)5761 (39.3)10,586 (36.1)\< 0.001Cefepime528 (3.6)713 (4.9)1241 (4.2)\< 0.001*ABF* Acute brain failure, *CHF* Congestive heart failure, *COPD* Chronic obstructive pulmonary disease, *DM* Diabetes Mellitus, *MI* Myocardial infarction, *AKI* Acute kidney injury

On multivariable analyses, the factors independently associated with AE included shock, midazolam infusion, AKI, renal disease (acute and chronic kidney injury), and cefepime use. Cefepime was associated with AE with an OR 1.24 (1.10--1.39) in patients with AKI and with an OR of 1.25 (1.11--1.40) in patients with renal disease as shown in Table [3](#Tab3){ref-type="table"}.Table 3Multivariable analyses for factors associated with development of acute encephalopathy (AE)Analyses with AKIOdds ratio95% confidence limits*p* valueShock1.2121.1551.272\< 0.001Midazolam infusion1.1711.1121.233\< 0.001Cefepime1.2421.1041.397\< 0.001Acute kidney injury (AKI)2.0651.9702.165\< 0.001Analyses with renal diseaseOdds ratio95% confidence limits*p* valueShock1.2531.1951.314\< 0.001Midazolam infusion1.1811.1221.244\< 0.001Cefepime1.2481.1101.402\< 0.001Renal disease (acute and chronic)1.8761.7891.966\< 0.001

The median duration of AE in our cohort was 17(IQR 4--52) hours. Patients who received cefepime had a longer AE duration \[5 (IQR 4--41) vs 4 (IQR 4--17) hours, *p* \< 0.001\] (supplementary table 2). Among patients who received Cefepime, AE duration was longer in patients with AKI \[7.2 (IQR 4--65) vs 4 (IQR 4--19) hours, *p* \< 0.001\] and those with renal disease \[5 (IQR 4--53) vs 4 (IQR 4--21) hours, *p* \< 0.001\].

The factors associated with AE duration on the multivariable analyses included shock, use of midazolam, use of cefepime, and the presence of AKI renal disease. Cefepime was associated with prolonged AE duration in patients with AKI \[parameter estimate 0.73 (95% CI 0.54--0.92), *p* \< 0.0001\] and those with renal disease \[parameter estimate 0.74 (95% CI 0.55--0.93), *p* \< 0.0001\] (supplementary table 3).

To further validate our findings, we performed sensitivity analyses after excluding patients with dementia (*n* = 505) and excluding the patients who did not receive any antibiotics (*n* = 13,881) during the ICU admission. The association of Cefepime with AE remained present. The results of these analyses are presented in the supplementary tables 4--7.

Discussion {#Sec8}
==========

Our large retrospective case--control study shows that cefepime use is associated with AE and longer AE duration in critically ill patients. Although it is more common in patients with acute and chronic renal disease, cefepime is also associated with AE in patients with normal renal function. In our study, the associations of cefepime with AE occurrence and AE duration were independent of other factors also associated with higher risk of AE, such as age, comorbidities, acute illness severity, shock, AKI, renal disease and infusion of midazolam. These findings were also present on sensitivity analyses after excluding patients with dementia and after excluding patients who did not receive antibiotics.

Cefepime has been known to cause neurotoxicity, especially patients with renal dysfunction in whom the dose of cefepime is not adequately adjusted, though nearly 15% of patients may still develop CIN despite adequate dosing \[[@CR3]--[@CR5], [@CR7]\]. CIN has been proposed to be caused by competitive binding of cefepime to GABA class receptors, thus interfering with inhibitory GABA neurotransmission and leading to central excitation \[[@CR17]\]. Furthermore the presence of inflammatory conditions, organ acid accumulations and renal dysfunction may predispose patients to disruptions in the blood brain barrier allowing increased CNS penetration of cefepime. \[[@CR18]\]

The true prevalence of CIN is unclear. Ranges have varied between 1 and 15% across various studies \[[@CR3], [@CR4], [@CR8]\]. In our initial cohort of nearly 160,000 patients who were admitted to the ICU, we found AE in 7.9% of patients exposed to cefepime and this rate was nearly twice as high in patients with renal failure. Yet, our study design can only describe associations and cannot establish causation.

The average time from the administration of cefepime to the development of signs of neurotoxicity was 4 days (IQR 1--6 days) and there was a gap of several days between the development of neurological signs and symptoms and cefepime discontinuation \[[@CR3]\]. Delayed recognition of neurotoxicity may be more common in patients who develop AE without positive neurological signs. Reported interventions for cefepime neurotoxicity include discontinuation of the drug or reduction in dose, treatment with one or more antiepileptic drugs and hemodialysis cases \[[@CR3], [@CR19]\].

A study by Grahl et al. found no association between cefepime use and the occurrence of delirium in the ICU \[[@CR9]\]. There were some key differences between the study by Grahl et al. and ours, although both of these studies excluded patients with primarily neurological disease. First, our study had a much larger size and therefore it may have identified associations that could have been missed on a smaller cohort. In fact, Grahl et al. found associations with delirium with first, second, and third-generation cephalosporins (likely more commonly used), but not with cefepime, suggesting that a methodological rather than a biological reason could explain the findings. Second, our study benefited from a case--control design, which increases the solidity of the analyses \[[@CR20]\]. Third, our population had more comorbidities \[Charlson score of 5.0 (IQR 3.0--7.0) vs 2 (IQR 1--4) in the cohort examined by Grahl et al.\]. Lastly, our finding that cefepime use was not only associated with the presence of AE, but also with its duration, lends further credence to the validity of the association.

The main limitations of our study are inherent to its retrospective design. While we tried to control for the most pertinent variables, there is a possibility that there might have potentially confounding factors, both known and unknown that might have influenced the occurrence of AE, especially in the ICU setting. Notably, we did not evaluate the effect of the concurrent use of other antimicrobials. Therefore, causality cannot be concluded from our results and the association of cefepime with AE requires further evaluation. Our hospital is a large referral center and hence the findings of this study might be affected by referral bias and might not be representative of the experience in other settings. Serum cefepime levels were not checked in our hospital practice and electroencephalogram (EEG) was not done routinely among these patients; hence we did not include that data in our analyses. Ideally, risk factors for AE should be examined starting from a large cohort of critically patients and comparing different exposures (such as antibiotics) in patients who develop AE vs those who do not; yet, we think that the clear differences in incidence and duration of AE in relation to cefepime exposure observed in our cohort are convincing. Despite these limitations, this is the largest case control study to our knowledge looking at the role of cefepime in the prevalence and duration of AE. Further prospective studies are needed to confirm these findings.

Conclusion {#Sec9}
==========

Cefepime use is associated with a greater likelihood of AE and longer AE duration in critically ill patients. These associations are stronger among patients with impaired renal function, but can also occur in patients without renal impairment. While our study cannot determine cefepime neurotoxicity as a cause of AE, the strength and independence of the associations identified in our analyses suggest that cefepime neurotoxicity should be considered as a potential modifiable factor for the development and persistence of AE in the ICU.
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